BioCentury | Mar 11, 2013
Clinical News

Caldolor ibuprofen regulatory update

...Cumberland said in its 4Q12 earnings that Australia approved a regulatory application from Phebra Pty. Ltd. (Sydney, Australia...
...adjunct to opioid analgesics and mild to moderate pain and to reduce fever in adults. Phebra...
BioCentury | Oct 25, 2010
Company News

Cumberland, Phebra sales and marketing update

...Phebra launched IV Acetadote acetylcysteine in Australia to treat acetaminophen poisoning. Phebra has exclusive, Australian marketing...
...Australian marketing rights to the IV acetylcysteine from Cumberland. Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), Nashville, Tenn. Phebra...
BioCentury | Oct 18, 2010
Clinical News

Caldolor: Phase III data

...groups in renal function, bleeding or serious adverse events. Data were published in Critical Care. Phebra...
BioCentury | Sep 6, 2010
Clinical News

Caldolor: Phase III data

...adverse events, blood transfusions or other serious adverse events. Data were published in Pain Medicine. Phebra...
BioCentury | Aug 23, 2010
Clinical News

Caldolor regulatory update

...Australian Therapeutic Good Administration ( TGA ) for Caldolor ibuprofen to treat pain and fever. Phebra...
BioCentury | May 17, 2010
Clinical News

Acetadote acetylcysteine regulatory update

...The Australian Therapeutic Goods Administration (TGA) approved Acetadote acetylcysteine to treat acetaminophen overdose. Phebra Pty. Ltd. (Sydney, Australia...
BioCentury | Nov 9, 2009
Company News

Cumberland, Phebra sales and marketing update

...Phebra received exclusive rights to commercialize Caldolor ibuprofen in Australia and New Zealand. Phebra will be...
...approved in the U.S. to treat pain and fever. Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), Nashville, Tenn. Phebra...
Items per page:
1 - 7 of 7
BioCentury | Mar 11, 2013
Clinical News

Caldolor ibuprofen regulatory update

...Cumberland said in its 4Q12 earnings that Australia approved a regulatory application from Phebra Pty. Ltd. (Sydney, Australia...
...adjunct to opioid analgesics and mild to moderate pain and to reduce fever in adults. Phebra...
BioCentury | Oct 25, 2010
Company News

Cumberland, Phebra sales and marketing update

...Phebra launched IV Acetadote acetylcysteine in Australia to treat acetaminophen poisoning. Phebra has exclusive, Australian marketing...
...Australian marketing rights to the IV acetylcysteine from Cumberland. Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), Nashville, Tenn. Phebra...
BioCentury | Oct 18, 2010
Clinical News

Caldolor: Phase III data

...groups in renal function, bleeding or serious adverse events. Data were published in Critical Care. Phebra...
BioCentury | Sep 6, 2010
Clinical News

Caldolor: Phase III data

...adverse events, blood transfusions or other serious adverse events. Data were published in Pain Medicine. Phebra...
BioCentury | Aug 23, 2010
Clinical News

Caldolor regulatory update

...Australian Therapeutic Good Administration ( TGA ) for Caldolor ibuprofen to treat pain and fever. Phebra...
BioCentury | May 17, 2010
Clinical News

Acetadote acetylcysteine regulatory update

...The Australian Therapeutic Goods Administration (TGA) approved Acetadote acetylcysteine to treat acetaminophen overdose. Phebra Pty. Ltd. (Sydney, Australia...
BioCentury | Nov 9, 2009
Company News

Cumberland, Phebra sales and marketing update

...Phebra received exclusive rights to commercialize Caldolor ibuprofen in Australia and New Zealand. Phebra will be...
...approved in the U.S. to treat pain and fever. Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), Nashville, Tenn. Phebra...
Items per page:
1 - 7 of 7